I was reading an article on MSN Money a few weeks ago about stocks that were undervalued, and this company was included on the list. The company was JDS Uniphase Corp. (Symbol: JDSU).

JDS Uniphase Corp. is the worldwide leading provider leading provider of broadband test & measurement solutions and optical products for communications, commercial and consumer markets. The company offers test and measurement systems and services for telecommunications service providers, cable operators, and network equipment manufacturers. In addition, the Company offers components, modules and subsystems for optical communication, display, security, medical/environmental instrumentation, decorative, aerospace and defense applications.

When the 4th quarter in 2005 ended, their revenue had already increased by 52% to $571.2 million. However, their net had also increased by 42% to $109.1 million - this higher net loss was mainly caused by research & development expenses. Overall, I think the company is doing pretty well. They were recently featured on MarketWatch as one of the undervalued stocks that currently represent great buys (it was highly recommended by Patrick Dorsey, the director of equity research at Chicago-based investment researcher Morningstar Inc.).

I have been watching this stock for quite some time and I have to tell you, I’m very impressed with its price performance.

Above is the price history (including the volume) in the past 12 months. The price does fluctuate a bit, but it keeps climbing and I’m not really sure when it’s going to reach its peak. Looking at the volume, this month represents the highest volume within the past 12 months. Heh..Looks like there were a lot of interests in this stock in the past couple of weeks.

I honestly think that this stock might have a great chance to hit a much higher price/share in the next few months. Given the industry that they’re in, the historical price data, and the services they offer, yes I’m absolutely convinced that the price will go much higher in the next few months….

Source: http://www.jdsu.com

Quote of the Day:
What’s my ROI [return-on-investment] on ecommerce? Are you crazy? This is Columbus in the New World. What was his ROI? - Andy Grove, former CEO of Intel

Founded in 1989, International Monetary Systems (IMS) serves more than 9,200 customers representing 14,000 cardholders in 32 U.S. markets. Based in New Berlin, Wis., IMS is one of the largest publicly traded barter companies in the world and is continually expanding its exchange locations. The company’s proprietary transaction network enables businesses and individuals to trade goods and services throughout North America. Using an electronic currency known as trade dollars, IMS exchanges allow companies to create cost savings and to improve operations by taking advantage of barter opportunities in their business models. Managed by seasoned industry veterans, IMS is a recognized member of the National Association of Trade Exchanges (NATE) and International Reciprocal Trade Association (IRTA).

Recently the company announced that their revenue has gone up to $538,000, which was 57% over January 2005. They were also recently featured in ValueRich Magazine, which was over 58,000 readers including 8,000 public company CEOs, fund managers, money managers, investment bankers, institutional and qualified private investors, brokers, security-related attorneys and accountants .

In the current ValueRich Magazine, which has over 58,000 readers including 8,000 public company CEOs, fund managers, money managers, investment bankers, institutional and qualified private investors, brokers, security-related attorneys and accountants. In addition to being featured in the magazine, they also did a presentation of their corporate overview of the company’s exciting growth strategy at the ValueRich Small-cap Financial Expo in Miami, March 8th - 9th.

The ValueRich Small-cap Financial Expo will showcase approximately 50 small-cap public companies to an audience of 1,500 investment professionals and high-net-worth investors at the Hotel InterContinental Miami. The ValueRich Small-cap Financial Expo is the only financial event in America where public company officers make traditional financial presentations and also are available for two solid days of unlimited one-on-one meetings at their executive suites on the expo floor.

Below is their price/share performance chart since July 2005.

As you see, the price hasn’t really changed much, it’s somewhat fluctuating - though it’s not fluctuating a lot. Looking at their price/share performance, I’m a little unsure whether this stock can be a good potential for short-term investment; however, based on their products and services, it might be good potential for a long-term investment. I guess for the next few months I’m going to be watching their price/share pretty closely. Who knows, maybe it’ll go up…Or down further.
Source: http://www.internationalmonetary.com

Quote of the Day:
Money does all things for reward. Some are pious and honest as long as they thrive upon it, but if the devil himself gives better wages, they soon change their party. - Seneca

There are over 8 million cancer patients in North America, with approximately 1 million more people developing cancer each year. Over one third of the population will develop cancer at some point during their life and over one-half a million people die from cancer each year. The new incidences of cancer, along with the maintenance of persons living with cancer continue to increase the demand for cancer products on a large scale.

The present world market for cancer therapeutics alone is approximately US$ 6.5 billion with an expected increase towards US$15 billion by the year 2002. The National Cancer Institute estimates the overall annual costs for cancer in the U.S. at US$104 billion with US$35 billion in direct medical costs and the remainder in productivity and mortality-related costs. Approximately one half of the direct costs are related to the treatment of breast, lung and prostate cancers. On a global basis, costs associated with cancer related illnesses are estimated at more than $150 billion. This is where BioCurex Inc. (Symbol: BOCX) enters the market.

BioCurex Inc. is currently developing these following products:

HISTOLOGY AND CYTOLOGY BioCurex’s Histo-RECAF™ is a special cancer detection kit for tissues that stains cancer cells brown, clearly distinguishing them from normal healthy cells. Pathologists are able to easily identify cancer cells under a conventional microscope for making a diagnosis.

LEUKEMIA Using our technology, leukemia cells can be “lit up” so that only infected blood cancer cells are isolated for targeted treatment. The clear implication of the BioCurex technology is that physicians can detect any recurrence of the blood cancer at a very early stage using equipment that is available today.

BLOOD AND SERUM TESTS Using our technology, a basic blood test can determine if a patient has cancer. Cancer cells shed our cancer marker RECAF™ into the blood stream where it is detected. Because of its powerful detection capability and simple execution, the Serum-RECAF™ will be a standardized blood test widely available in any clinical laboratory. Physicians can then use Serum-RECAF™ as frequently as required for both the initial screening of patients with symptoms, and monitoring of those patients who have been previously treated for cancer.

TUMOR IMAGING Once cancer has been diagnosed, it is crucial to determine its location and size. Because the RECAF™ technology effectively detects cancer cells, cancer tissue can be targeted with special compounds administered to the patient. Since only cancer cells are selected, tumor locations can then be imaged using standard equipment.Recently they announced that Dr. Steward Sell has joined the Scientific Advisory Board of BioCurex Inc. Dr. Steward Sell is an internationally renowned physician and scientist in the cancer and stem cell fields. In addition to obtaining his medical degree at the University of Pittsburgh, his residency in Pathology at Massachusetts General Hospital, and research in Immunology at National Institute of Health, Bethesda and University of Birmingham, he has also received many awards including the Virchow Award (in honor of the recognized father of pathology), Legacy Laureate of the University of Pittsburgh, (which recognizes the University’s most distinguished graduates), Distinguished Scientist by the International Academy of Tumor Marker Oncology, the Gary Miller Memorial Award from the American Association for Cancer Research (AACR) and recently, a special award from the AACR for his contributions to teaching principles of cancer biology over the last 25 years. Yupp, that’s a pretty distinguished resume, if I might add

Below is their stock performance for the past 6 months.

Source: http://biocurex.com

Quote of the Day:
The stocks I try to buy are the very stocks that traditional fund managers try to overlook. In other words, I continue to think like an amateur as frequently as possible. - Peter Lynch